Situación de la enfermedad renal crónica en América Latina, con énfasis en la enfermedad renal diabética: dificultades y desafíos
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rico-Fontalvo, Jorge | |
| dc.contributor.author | Elbert, Alicia | |
| dc.contributor.author | Lorca, Eduardo | |
| dc.contributor.author | Daza-Arnedo, Rodrigo | |
| dc.contributor.author | Castellaro, Carlos | |
| dc.contributor.author | Villavicencio, Vanessa | |
| dc.contributor.author | Rosa-Diez, Guillermo | |
| dc.contributor.author | Bonanno-Hidalgo, Carlos | |
| dc.contributor.author | Sánchez-Polo, Vicente | |
| dc.contributor.author | Correa-Rotter, Ricardo | |
| dc.date.accessioned | 2025-01-14T14:29:06Z | |
| dc.date.available | 2025-01-14T14:29:06Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | La enfermedad renal crónica (ERC) es un grave problema de salud pública en todo el mundo, con elevada prevalencia en la población adulta y cuyo diagnóstico con frecuencia ocurre tardíamente. Con el objetivo de un cambio de visión para generar propuestas y un llamado a la acción acerca de la forma de afrontar a la ERC y el síndrome cardio-reno-metabólico, se llevó a cabo un encuentro de expertos en nefrología, con participantes de Argentina, Brasil, Chile, Colombia, Ecuador, El Salvador, Guatemala, México, Nicaragua y República Dominicana. A partir de la revisión de la mejor evidencia disponible y bajo la óptica de la experiencia en la práctica diaria acerca de las dificultades y las oportunidades para optimizar el diagnóstico precoz y el tratamiento de la ERC, con énfasis en la enfermedad renal diabética, se presenta una descripción del escenario actual, los retos y las propuestas para mejorar esta situación en la región. | spa |
| dc.description.abstract | Chronic kidney disease (CKD) is a serious public health problem worldwide, with a high prevalence in the adult population and often lately diagnosed. A meeting of experts in nephrology, with participants from Argentina, Brazil, Chile, Colombia, Ecuador, El Salvador, Guatemala, Mexico, Nicaragua and the Dominican Republic, was held with the aim of generating proposals and a call to action on how to deal with CKD and cardio-renal-metabolic syndrome. Based on a review of the best available evidence and from the perspective of experience in daily practice about the difficulties and opportunities for optimizing early diagnosis and treatment of CKD, with emphasis on diabetic kidney disease, a description of the current scenario, the challenges and proposals for improving this situation in the region are presented. | spa |
| dc.format.mimetype | ||
| dc.identifier.doi | DOI: 10.24875/NEFRO.M24000055 | |
| dc.identifier.issn | 24449032 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16081 | |
| dc.identifier.url | https://www.nefrologialatinoamericana.com/frame_esp.php?id=161 | |
| dc.language.iso | spa | |
| dc.publisher | Sociedad Latinoamericana de Nefrología e Hipertensión | spa |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.source | Nefrología Latinoamericana | spa |
| dc.source | Nefro Latinoam. | eng |
| dc.subject | Enfermedad renal crónica | spa |
| dc.subject | Diabetes | spa |
| dc.subject | Enfermedad renal diabética | spa |
| dc.subject | Obesidad | spa |
| dc.subject | Epidemiología | spa |
| dc.subject | Implementación | spa |
| dc.subject | Políticas de salud renal | spa |
| dc.subject.keywords | Chronic kidney disease | eng |
| dc.subject.keywords | Diabetic kidney disease | eng |
| dc.subject.keywords | Obesity | eng |
| dc.subject.keywords | Epidemiology | eng |
| dc.subject.keywords | Implementation | eng |
| dc.subject.keywords | Kidney health policy | eng |
| dc.title | Situación de la enfermedad renal crónica en América Latina, con énfasis en la enfermedad renal diabética: dificultades y desafíos | spa |
| dc.title.translated | Situation of chronic kidney disease in Latin America, with emphasis on diabetic kidney disease: difficulties and challenges | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Correa-Rotter R, Méndez Durán A, Vallejos A, Rico-Fontalvo J, Cusumano AM, Rosa-Diez GJ, et al. Unmet needs of CKD in Latin America: a review from expert virtual working group. Kidney Int Rep. 2023;8:954-67. | eng |
| dcterms.references | Institute for Health Metrics and Evaluation. Global Burden of Disease (GBD). 2024. (Consultado el 15-10-2024.) Disponible en: https://www. healthdata.org/research-analysis/gbd. | eng |
| dcterms.references | World Health Organization. Global Health Observatory. 2024. (Consultado el 15-10-2024.) Disponible en: https://www.who.int/data/gho. | eng |
| dcterms.references | Wainstein M, Bello AK, Jha V, Harris DCH, Levin A, González-Bedat MC, et al. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America. Kidney Int Suppl. 2021;11:e35-46. | eng |
| dcterms.references | Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020;395:662-4. | eng |
| dcterms.references | Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10:447-58. | eng |
| dcterms.references | Obrador G, Álvarez-Estévez G, Bellorín E, Bonanno-Hidalgo C, Clavero R, Correa-Rotter R, et al. Documento de consenso sobre nuevas terapias para retrasar la progresión de la enfermedad renal crónica con énfasis en los iSGLT-2: implicaciones para Latinoamérica. Nefro Latinoam. 2024;21(Supl):1-18. | spa |
| dcterms.references | Bravo-Zuñiga JI, Carlino-Bauza MC, Ríos-Sarro PG, Zúñiga-San Martín CA, Cueto-Manzano AM, Zúñiga-Saravia EA, et al. Aportes para la creación de programas de salud renal en Latinoamérica, Comité de Salud Renal de la SLANH. Nefro Latinoam. 2024;21:40-52. | spa |
| dcterms.references | Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-314. | eng |
| dcterms.references | Zuniga C, Riquelme C, Muller H, Vergara G, Astorga C, Espinoza M. Using telenephrology to improve access to nephrologist and global kidney management of CKD primary care patients. Kidney Int Rep. 2020;5:920-3. | eng |
| dcterms.references | Hajar R. Diabetes as «coronary artery disease risk equivalent»: a historical perspective. Heart Views. 2017;18:34-7. | eng |
| dcterms.references | Sattar N, Rawshani A, Franzén S, Rawshani A, Svensson AM, Rosengren A, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139:2228-37. | eng |
| dcterms.references | Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043-140. | eng |
| dcterms.references | Bedo D, Beaudrey T, Florens N. Unraveling chronic cardiovascular and kidney disorder through the butterfly effect. Diagnostics. 2024;14:463. | eng |
| dcterms.references | Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148:1606-35. | eng |
| dcterms.references | Nawaz S, Chinnadurai R, Al‐Chalabi S, Evans P, Kalra PA, Syed AA, et al. Obesity and chronic kidney disease: a current review. Obes Sci Pract. 2023;9:61-74. | eng |
| dcterms.references | Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165-75. | eng |
| dcterms.references | Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med. 2022;387:2021-32. | eng |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Rodríguez-Yáñez T, Martínez-Ávila MC, Cabrales J, Cardona-Blanco MX, et al. Inflammation and diabetic kidney disease: new perspectives. J Biomed Res Environ Sci. 2022; 3:779-86. | eng |
| dcterms.references | Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366:2026-33. | eng |
| dcterms.references | Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9. | eng |
| dcterms.references | Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60. | eng |
| dcterms.references | Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788-801. | eng |
| dcterms.references | Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-46. | eng |
| dcterms.references | Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. | eng |
| dcterms.references | The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117-27. | eng |
| dcterms.references | Cortinovis M, Perico N, Cattaneo D, Remuzzi G. Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis. 2009;3:133-43. | eng |
| dcterms.references | Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403:379-90. | eng |
| dcterms.references | Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252-63. | eng |
| dcterms.references | Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653-62. | eng |
| dcterms.references | Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024; 391:109-21. | eng |
| dcterms.references | Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |